Q-omics provides the consensus-scored CCL11 profile across patient tissues and cancer cell-line models. CCL11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCL11 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CCL11 RNA expression shows 11,401 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight HNSC, and OV as cancer lineages where CCL11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCL11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCL11 survival associations across molecular data types. CCL11 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCL11 RNA expression–survival associations across cancer types. High CCL11 expression shows unfavorable associations in KIRC, KIRP, OV and UCEC, but favorable associations in HNSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCL11 RNA expression.
This table summarizes CCL11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCL11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCL11 shows lower tumor expression in KIRC, KIRP, KICH and COAD and higher tumor expression in HNSC and BRCA. The HNSC box plot shows higher CCL11 RNA expression in tumor versus normal tissue (log2 FC = +2.896, t-test p < 0.001).
This table shows molecular features associated with CCL11 in patient tissues and cancer cell lines. In patient samples, CCL11 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set. In cancer cell lines, CCL11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
